Lab to Lives · Dec 17, 2025 · 29 min
Inside Sionna’s Bid To Normalize CFTR Function
0:00 · Setting The Mission And Guests-29:41
transcript
show notes
Two leaders from Sionna Therapeutics walk through a 15‑year journey from Genzyme science to a public company advancing NBD1‑targeted therapies in cystic fibrosis. We examine why most patients still fall short of normal CFTR, how a predictive assay de‑risks choices, and what it takes to finance, hire, and execute with patients as the North Star.
Visit: sionnatx.com
________
Reach out to Ivanna Rosendal
Join the conversation on our LinkedIn page
Visit www.labtolives.com
Hosts
links7
